October 24, 2019 08:27 AM EDTUpdated October 25, 04:07 AM
Bioregnum
R&D
Pharma
Opinion

From $0 to $12B in an in­stant. Here's why bio­phar­ma loves risky Alzheimer's stud­ies

Any­one who is strug­gling to un­der­stand why bio­phar­ma com­pa­nies are will­ing to sink bil­lions in­to piv­otal tri­als built around failed the­o­ries on how to …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

As­traZeneca re­ports Phase 3 win for Imfinzi; Roche to build new man­u­fac­tur­ing site in Chi­na

Chron­ic care start­up Oma­da Health files to go pub­lic

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times